izuralimab

{
  "id": "MLC-T-ONC-014612",
  "term": "izuralimab",
  "field": "Oncology and biomedicine",
  "definition": "A humanized, Fc-engineered bispecific monoclonal antibody directed against both the human negative immunoregulatory checkpoint receptor, programmed cell death protein 1 (PD-1; PCD-1; CD279), and inducible T-cell co-stimulator (ICOS; CD278), with potential immunomodulating and antineoplastic activities. Upon administration, izuralimab targets and binds to both PD-1 and ICOS expressed on certain T cells, including tumor-infiltrating lymphocytes (TILs). This prevents the activation of PD-1 by its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2), and stimulates ICOS-mediated signaling, which promotes the activation of T cells and enhances T-cell-mediated immune responses against tumor cells. Combined PD-1 blockade and ICOS stimulation may enhance T-cell activation and proliferation more than targeting each receptor individually. The engineered Fc domain increases the stability and half-life of the antibody.",
  "synonyms": [
    "PD1 x ICOS bispecific monoclonal antibody XmAb23104",
    "anti-PD1/anti-ICOS bispecific monoclonal antibody XmAb23104",
    "anti-PD1/ICOS bispecific monoclonal antibody XmAb23104"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/izuralimab/"
}